| 67 | 0 | 33 |
| 下载次数 | 被引频次 | 阅读次数 |
秋水仙碱作为一种传统的抗炎药物，近年来在冠心病治疗领域展现出潜在的应用价值。基础研究表明，秋水仙碱可通过抑制NLRP3炎症小体、调节免疫细胞功能及细胞内信号通路等多途径抑制血管炎症反应，增强斑块稳定性。临床研究显示，低剂量秋水仙碱可显著降低稳定性冠心病患者的主要不良心血管事件风险。然而，其在急性冠脉综合征患者中的疗效存在争议，因此，文章系统总结了秋水仙碱在心血管疾病中的作用机制与临床研究进展，以期为临床决策提供参考。
Abstract：Colchicine, as a traditional anti-inflammatory drug, has demonstrated potential application value in the field of coronary heart disease(CHD) treatment in recent years. Basic research indicates that colchicine can inhibit vascular inflammatory responses and enhance plaque stability through multiple pathways, including suppressing the NLRP3 inflammasome, modulating immune cell functions, and regulating intracellular signaling pathways. Clinical studies have shown that low-dose colchicine can significantly reduce the risk of major adverse cardiovascular events in patients with stable CHD. However, its efficacy in patients with acute coronary syndrome remains controversial. Therefore, this article systematically summarizes the mechanism of action and the progress of clinical research on colchicine in cardiovascular diseases, aiming to provide a reference for clinical decision-making.
[1]CHO S M J, KOYAMA S, HONIGBERG M C, et al. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events:a population-based cohort study[J]. European Heart Journal, 2023, 44(36):3456-3465.
[2]RIDKER P M. Targeting residual inflammatory risk:the next frontier for atherosclerosis treatment and prevention[J].Vascular Pharmacology, 2023, 153:107238.
[3]RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. The New England Journal of Medicine, 2017, 377(12):1119-1131.
[4]Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T,Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; Lo Do Co2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi:10.1056/NEJMoa2021372. Epub 2020 Aug 31. PMID:32865380.
[5]VIRANI S S, NEWBY L K, ARNOLD S V, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease:a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2023, 148(9):e9-e119.
[6]WANG H, FENG W, WANG J, et al. Colchicine alleviates atherosclerosis combined with diabetes mellitus by targeting PIM2 and regulating the NF-κB signaling pathway[J]. Phytomedicine, 2025, 147:157194.
[7]YU M, YANG Y, DONG S L, et al. Effect of colchicine on coronary plaque stability in acute coronary syndrome as assessed by optical coherence tomography:the COLOCT randomized clinical trial[J]. Circulation, 2024, 150(13):981-993.
[8]MARTÍNEZ G J, ROBERTSON S, BARRACLOUGH J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome[J]. Journal of the American Heart Association, 2015,4(8):e002128.
[9]BUCKLEY L F, DORBALA P, CLAGGETT B L, et al. Circulating neutrophil-related proteins associate with incident heart failure and cardiac dysfunction:the ARIC study[J]. European Journal of Heart Failure, 2023, 25(11):1923-1932.
[10]VAIDYA K, TUCKER B, KURUP R, et al. Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention[J]. Journal of the American Heart Association, 2021,10(1):e018993.
[11]TANG J, LI T, XIONG X, et al. Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells[J]. Journal of Nanobiotechnology,2023, 21(1):460.
[12]SCHWARZ N, FERNANDO S, CHEN Y C, et al. Colchicine exerts anti-atherosclerotic and-plaque-stabilizing effects targeting foam cell formation[J]. FASEB Journal, 2023, 37(4):e22846.
[13]YU Y, ZHOU M, LONG X, et al. Study on the mechanism of action of colchicine in the treatment of coronary artery disease based on network pharmacology and molecular docking technology[J]. Frontiers in Pharmacology, 2023, 14:1147360.
[14]TANG Y, SHI C, QIN Y, et al. Network pharmacology-based investigation and experimental exploration of the antiapoptotic mechanism of colchicine on myocardial ischemia reperfusion injury[J]. Frontiers in Pharmacology, 2021, 12:804030.
[15]NIDORF S M, FIOLET A T L, MOSTERD A, et al. Colchicine in patients with chronic coronary disease[J]. The New England Journal of Medicine, 2020, 383(19):1838-1847.
[16]TARDIF J C, KOUZ S, WATERS D D, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J].The New England Journal of Medicine, 2019, 381(26):2497-2505.
[17]TONG D C, QUINN S, NASIS A, et al. Colchicine in patients with acute coronary syndrome:the Australian COPS randomized clinical trial[J]. Circulation, 2020, 142(20):1890-1900.
[18]DEFTEREOS S, GIANNOPOULOS G, RAISAKIS K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J]. Journal of the American College of Cardiology, 2013, 61(16):1679-1685.
[19]D'ENTREMONT M A, LEE S F, MIAN R, et al. Design and rationale of the CLEAR SYNERGY(OASIS 9)trial:a2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction[J]. American Heart Journal, 2024, 275:173-182.
[20]BUCKLEY L F, LIBBY P. Colchicine's role in cardiovascular disease management[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44(5):1031-1041.
[21]STEWART S, YANG K C K, ATKINS K, et al. Adverse events during oral colchicine use:a systematic review and meta-analysis of randomised controlled trials[J]. Arthritis Research&Therapy, 2020, 22(1):28.
[22]CONEN D, KE WANG M, POPOVA E, et al. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery(COP-AF):an international randomised trial[J]. Lancet, 2023, 402(10413):1627-1635.
[23]WIGGINS B S, SASEEN J J, PAGE R L 2nd, et al. Recommendations for management of clinically significant drugdrug interactions with statins and select agents used in patients with cardiovascular disease:a scientific statement from the American Heart Association[J]. Circulation, 2016, 134(21):e468-e495.
[24]DAVIS M W, WASON S. Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions[J]. Clinical Drug Investigation, 2014, 34(4):259-267.
基本信息:
DOI：10.16068/j.1000-1824.2026.02.004
中图分类号:R541.4
引用信息:
[1]高柠檬,玄春花,洪兰.秋水仙碱治疗冠心病研究进展[J].延边大学医学学报,2026,49(02):12-15+19.DOI:10.16068/j.1000-1824.2026.02.004.
2026-01-13
2026
2026-01-13
2026
1
2026-02-28
2026-02-28